Anvisa probes vision loss linked to GLP-1 weight-loss drugs

Brazil's health regulator Anvisa is investigating reports of a rare optic nerve vascular injury in patients using GLP-1 agonist weight-loss medications. The condition, which clogs blood vessels supplying the optic nerve, is a potential new safety signal for a widely prescribed drug class. The investigation is preliminary, and causality has not been established.